GFAP and myeloid sarcoma: In our DOT-MS cohort (NCT04260711), we therefore investigated the ability of NfL and GFAP to discriminate disease activity and stable disease in participants with long-term stable MS who continued or discontinued first-line disease-modifying therapy (DMT).